Azenta (BA3) AI Stock Analysis

Azenta

(BX Swiss:BA3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring revenue and biorepository momentumA revenue base with more than half recurring provides greater visibility than project-only demand and supports repeat consumables, services, and biorepository activity. Growth in these businesses can improve customer retention and make future revenue less dependent on individually timed capital projects.

Negative Factors

Persistent unprofitabilityNegative operating earnings and a deeply negative net margin show that Azenta is not yet consistently converting revenue into profit. Until operating costs and other charges are better controlled, growth may add limited earnings value and internal funding capacity will remain constrained.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other internatio...

Azenta Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q3-2026)|Next Earnings Date:Nov 09, 2026

Earnings Call SentimentNeutral

The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.

Positive Updates

Revenue Beat and Organic Growth

Total revenue of $161.0M in Q3, up 12% reported and 9% organically, ahead of company expectations.

Negative Updates

Overall and SMS Gross Margin Pressure

Total gross margin was 46.2%, down 140 basis points year-over-year. Sample Management Solutions gross margin declined sharply, to 45.9% for the quarter, down ~750 basis points versus prior year, driven by automated stores, cryogenic systems, unfavorable fixed cost absorption and quality remediation.

Company Guidance

Azenta updated its fiscal 2026 outlook, now expecting reported revenue of $613–$618 million and organic revenue roughly flat to up 1% year‑over‑year (improved from prior -2% to +1%); full‑year adjusted EBITDA is guided to $59–$62 million (Q4 adjusted EBITDA $20–$23 million) with Q4 organic revenue expected to decline low single digits versus a tough Q4 comp. Management expects full‑year free cash flow to improve ~10%–15% YoY, anticipates UK Biocentre will dilute margins by ~30 basis points, and reiterated remediation costs for automated stores of ~$5–$6 million for FY26 (about $1 million incurred in Q3). For context, Q3 revenue was $161 million (up 12% reported / 9% organic), Q3 adjusted EBITDA margin was ~11.4% (down 60 bps YoY, up 610 bps sequential), gross margin was 46.2% (down 140 bps), cash and equivalents were $529 million, and the company repurchased ~2.3 million shares for $50 million while completing the $63 million divestiture of B Medical Systems.

Azenta Risk Analysis

Azenta disclosed 35 risk factors in its most recent earnings report. Azenta reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Azenta Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:BA3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RGEN	68Neutral	$11.23B	-823.57	-0.56%	―	13.80%	-811.00%
AVTR	66Neutral	$10.88B	31.14	5.96%	―	0.92%	―
BDX	63Neutral	$53.90B	59.82	3.79%	2.00%	-2.56%	-40.38%
HBIO	52Neutral	$40.52M	-3.70	-92.01%	―	-1.06%	82.17%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CH:BA3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BDX	Becton, Dickinson and Co	198.60	61.33	44.68%
HBIO	Harvard Bioscience	8.60	2.44	39.54%
RGEN	Repligen	172.95	26.02	17.71%
AVTR	Avantor	15.61	4.03	34.80%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Azenta AI Stock Analysis